Ignite Creation Date:
2025-12-24 @ 5:33 PM
Ignite Modification Date:
2025-12-25 @ 3:05 PM
Study NCT ID:
NCT07257068
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-02
First Post:
2025-11-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
Sponsor:
M.D. Anderson Cancer Center
Organization:
Study Overview
Official Title:
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
Detailed Description:
Primary Objective
1\. To estimate the efficacy of infliximab in reversing insulin dependence in CIADM.
Secondary Objective
1. To evaluate the safety of infliximab when used for CIADM.
2. To estimate the duration of time off insulin for patients who are able to discontinue insulin.
1\. To estimate the efficacy of infliximab in reversing insulin dependence in CIADM.
Secondary Objective
1. To evaluate the safety of infliximab when used for CIADM.
2. To estimate the duration of time off insulin for patients who are able to discontinue insulin.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| NCI-2025-08623 | OTHER | NCI-CTRP Clinical Registry | View |